首页 | 本学科首页   官方微博 | 高级检索  
     

参芪平消胶囊配合化疗治疗晚期非小细胞肺癌临床研究
引用本文:王晓瑜,王黎. 参芪平消胶囊配合化疗治疗晚期非小细胞肺癌临床研究[J]. 中国中医药信息杂志, 2005, 12(10): 10-12
作者姓名:王晓瑜  王黎
作者单位:1. 郑州铁路局中心医院,河南,郑州,450052
2. 河南省肿瘤医院,河南,郑州,450003
摘    要:目的比较参芪平消胶囊加化疗与单纯化疗对晚期非小细胞肺癌的疗效、毒副反应及免疫功能的影响。方法将126例晚期非小细胞肺癌患者随机分为两组。治疗组采用参芪平消胶囊加化疗,化疗方案同对照组。对照组采用NP方案,21d为1个周期,治疗2~4个周期。结果治疗组完全缓解1例,部分缓解36例,有效率、进展率分别为58.73%、14.28%;对照组完全缓解1例,部分缓解25例,有效率、进展率为41.93%、30.64%。两组有效率比较,差异无显著性(P>0.05);两组进展率比较,差异有显著性(P<0.05)。治疗组血液毒副反应、胃肠道反应均低于对照组(P<0.01);生存质量、NK细胞活性均高于对照组(P<0.01)。治疗组2年、3年生存率(32.20%、18.64%)高于对照组(15.25%、3.39%),有显著性差异(P<0.05、P<0.01)。结论参芪平消胶囊配合化疗治疗晚期非小细胞肺癌可增强化疗耐受性,减轻毒副反应,保护患者免疫功能,提高生存质量,延长患者生存期。

关 键 词:参芪平消胶囊  化疗  晚期非小细胞肺癌
文章编号:1005-5304(2005)10-0010-03
收稿时间:2005-03-07
修稿时间:2005-03-07

Clinical Study of Using Shenqi Pingxiao Capsule with Chemotherapy in Treating Nonmicrocytic Lung Cancer of Later Stage
WANG Xiao-yu,WANG Li. Clinical Study of Using Shenqi Pingxiao Capsule with Chemotherapy in Treating Nonmicrocytic Lung Cancer of Later Stage[J]. Chinese Journal of Information on Traditional Chinese Medicine, 2005, 12(10): 10-12
Authors:WANG Xiao-yu  WANG Li
Abstract:Objective Compare the therapeutic effects, the toxic and side effects and influences in immune function of Shenqi Pingxiao capsule with chemotherapy and single chemotherapy in treating non-microcytic lung cancer of later stage. Methods 126 cases of non-microcytic lung cancer of later stage were randomly divided into two groups. Trial group received Shenqi Pingxiao capsule with chemotherapy (NP programme). Control group received NP programme for two to four periodic, 21 days was one periodic. Results In CR, PR, the effective and the progressive rate after treatment, trial group got one case, 36 cases and 58.73%, 14.28%. While control group got one case, 25 cases and 41.93%, 0.64%. There was no obvious difference in the effective rate between both groups (P>0.05) and apparent differentce in the progressive rate (P<0.05). In the toxic and side effects and the gastrointestinal reaction, trial group was lower than control group (P<0.01). Life quality and NK cell activity of trial group were both higher than control group (P<0.01). In two or three years' survival probability, there was obvious difference (P<0.05,P<0.01) between trial group (32.20%,18.64%) and control group (15.25%,3.39%), trial group was higher. Conclusion Shenqi Pingxiao capsule with chemotherapy in treating non-microcytic lung cancer of later stage has the effects of strengthening the tolerance to chemotherapy, relieving the toxic and side effects, protecing immune function, increasing life quantity and extending lifetime.
Keywords:Shenqi Pingxiao capsule  chemotherapy  non-microcytic lung cancer of later stage
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号